tbuckley/cabot-search huggingface dataset:
Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition
Authors: Kai Shi, Yi Zhao, Lei Miao, Andrew Satterlee, Matthew Haynes, Cong Luo, Sara Musetti, Leaf Huang
Journal: Molecular Therapy (2017)

The success of small interfering RNA (siRNA)-mediated gene silencing for cancer therapy is still limited because of its instability and poor intracellular internalization. Traditional cationic carriers cannot adequately meet the need for clinical application of siRNA. We herein report a dual-functional liposome containing a cholesterol derivative of metformin, i.e., LipoMET, which takes advantage of the fusogenic activity as well as intrinsic tumor apoptosis inducing ability of biguanide moiety to achieve a combinational anti-oncogenic effect. In this study, the vascular endothelial growth factor (VEGF)-specific siRNAs were first electrostatically condensed into a ternary nanocomplex composed of polycation and hyaluronate, which was subsequently enveloped by LipoMET through membrane fusion. In comparison with common cationic control group, the resulting envelope-type nanoparticles (PH@LipoMET nanoparticles [NPs]) showed the ability of rapid cellular internalization and effective endosomal escape of siRNA during intracellular trafficking studies. Systemic administration of the targeted LipoMETs was capable of inducing apoptosis and tumor growth inhibition in the NCI-H460 xenograft model. When carrying VEGF-specific siRNAs, PH@LipoMET NPs remarkably downregulated the expression of VEGF and led to even more tumor suppression in vivo. Thus, LipoMET originated envelope-type nanoparticles may serve as a potential dual-functional siRNA delivery system to improve therapeutic effect of oncogene silencing.
Comprehensive Plasma Cytokine Profiling in Polycythemia Vera: Comparison with Myelofibrosis and Clinical Correlates,
Authors: Rakhee Vaidya, Nanna Sulai, Shaina A Rozell, Sania S Raza, Sameer Parikh, Thitina Jimma, Christy Finke, Terra L Lasho, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2011)
Tackling inpatient penicillin allergies: Assessing tools for antimicrobial stewardship
Authors: Kimberly G. Blumenthal, Paige G. Wickner, Shelley Hurwitz, Nicholas Pricco, Alexandra E. Nee, Karl Laskowski, Erica S. Shenoy, Rochelle P. Walensky
Journal: Journal of Allergy and Clinical Immunology (2017)

Reported penicillin allergy rarely reflects penicillin intolerance. Failure to address inpatient penicillin allergies results in more broad-spectrum antibiotic use, treatment failures, and adverse drug events.We aimed to determine the optimal approach to penicillin allergies among medical inpatients.We evaluated internal medicine inpatients reporting penicillin allergy in 3 periods: (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline application with decision support (APP). The primary outcome was use of a penicillin or cephalosporin, comparing interventions to SOC using multivariable logistic regression.There were 625 patients: SOC, 148; ST, 278; and APP, 199. Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allergic. In the APP period, there were 292 unique Web site views; 112 users (38%) completed clinical decision support. Although ST period patients did not have increased odds of penicillin or cephalosporin use overall (adjusted odds ratio [aOR] 1.3; 95% CI, 0.8-2.0), we observed significant increased odds of penicillin or cephalosporin use overall in the APP period (aOR, 1.8; 95% CI, 1.1-2.9) and in a per-protocol analysis of the skin tested subset (aOR, 5.7; 95% CI, 2.6-12.5).Both APP and ST-when completed-increased the use of penicillin and cephalosporin antibiotics among inpatients reporting penicillin allergy. While the skin tested subset showed an almost 6-fold impact, the computerized guideline significantly increased penicillin or cephalosporin use overall nearly 2-fold and was readily implemented.
Sudden and Unexpected Deaths in Young Adults
Authors: Lewis Kuller
Journal: JAMA (1966)

An epidemiological study of sudden and unexpected death was conducted in Baltimore city during 1964 and 1965. Of the 322 nontraumatic deaths reviewed, 101 (31.4%) were sudden and unexpected. Sudden, unexpected deaths were more common in Negroes and men. Alcoholism and fatty liver was the leading cause of sudden, unexpected death, accounting for 27.7% of the sudden deaths, while 21.8% were due to arteriosclerotic heart disease.
Induction of Apoptosis in Multiple Myeloma by Ligands of Peroxisome Proliferator-Activated Receptor γ (PPAR-γ).
Authors: Jan Eucker, Katharina Baengeroth, Ivana Zavrski, Holger Krebbel, Chuanbing Zang, Ulrike Heider, Christian Jakob, Elena Elstner, Kurt Possinger, Orhan Sezer
Journal: Blood (2004)
Prevalence and Predictors of Self-Reported Neuropsychological Impairment in Patients Undergoing Hematopoietic Cell Transplantation (HCT) - Impact On Return to Work After HCT.
Authors: Alysia Bosworth, Lennie Wong, Sunita Patel, Doojduen Villaluna, Mitzi Gonzales, Marcia Grant, Stephen J. Forman, Smita Bhatia
Journal: Blood (2009)
Socio-environmental correlates of physical activity in patients with chronic obstructive pulmonary disease (COPD)
Authors: Ane Arbillaga-Etxarri, Elena Gimeno-Santos, Anael Barberan-Garcia, Marta Benet, Eulàlia Borrell, Payam Dadvand, Maria Foraster, Alicia Marín, Mònica Monteagudo, Robert Rodriguez-Roisin, Pere Vall-Casas, Jordi Vilaró, Judith Garcia-Aymerich
Journal: Thorax (2017)

<h3>Background</h3> Study of the causes of the reduced levels of physical activity in patients with COPD has been scarce and limited to biological factors. <h3>Aim</h3> To assess the relationship between novel socio-environmental factors, namely dog walking, grandparenting, neighbourhood deprivation, residential surrounding greenness and residential proximity to green or blue spaces, and amount and intensity of physical activity in COPD patients. <h3>Methods</h3> This cross-sectional study recruited 410 COPD patients from five Catalan municipalities. Dog walking and grandparenting were assessed by questionnaire. Neighbourhood deprivation was assessed using the census Urban Vulnerability Index, residential surrounding greenness by the satellite-derived Normalized Difference Vegetation Index, and residential proximity to green or blue spaces as living within 300 m of such a space. Physical activity was measured during 1 week by accelerometer to assess time spent on moderate-to-vigorous physical activity (MVPA) and vector magnitude units (VMU) per minute. <h3>Findings</h3> Patients were 85% male, had a mean (SD) age of 69 (9) years, and post-bronchodilator FEV<sub>1</sub> of 56 (17) %pred. After adjusting for age, sex, socio-economic status, dyspnoea, exercise capacity and anxiety in a linear regression model, both dog walking and grandparenting were significantly associated with an increase both in time in MVPA (18 min/day (p&lt;0.01) and 9 min/day (p&lt;0.05), respectively) and in physical activity intensity (76 VMU/min (p=0.05) and 59 VMUs/min (p&lt;0.05), respectively). Neighbourhood deprivation, surrounding greenness and proximity to green or blue spaces were not associated with physical activity. <h3>Conclusions</h3> Dog walking and grandparenting are associated with a higher amount and intensity of physical activity in COPD patients. <h3>Trial registration number</h3> Pre-results, NCT01897298.
Recent advances in the understanding of severe cutaneous adverse reactions
Authors: N.R. Adler, A.K. Aung, E.N. Ergen, J. Trubiano, M.S.Y. Goh, E.J. Phillips
Journal: British Journal of Dermatology (2017)

Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. This review explores evolving knowledge of the immunopathogenic mechanisms, pharmacogenomic associations, in vivo and ex vivo diagnostics for causality assessment, and medication cross‐reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematized framework for translating epidemiological, clinical and immunopathogenetic advances into preventive efforts and improved outcomes for patients.
Erratum: Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Authors: Tasha E Fingerlin, Elissa Murphy, Weiming Zhang, Anna L Peljto, Kevin K Brown, Mark P Steele, James E Loyd, Gregory P Cosgrove, David Lynch, Steve Groshong, Harold R Collard, Paul J Wolters, Williamson Z Bradford, Karl Kossen, Scott D Seiwert, Roland M du Bois, Christine Kim Garcia, Megan S Devine, Gunnar Gudmundsson, Helgi J Isaksson, Naftali Kaminski, Yingze Zhang, Kevin F Gibson, Lisa H Lancaster, Joy D Cogan, Wendi R Mason, Toby M Maher, Philip L Molyneaux, Athol U Wells, Miriam F Moffatt, Moises Selman, Annie Pardo, Dong Soon Kim, James D Crapo, Barry J Make, Elizabeth A Regan, Dinesha S Walek, Jerry J Daniel, Yoichiro Kamatani, Diana Zelenika, Keith Smith, David McKean, Brent S Pedersen, Janet Talbert, Raven N Kidd, Cheryl R Markin, Kenneth B Beckman, Mark Lathrop, Marvin I Schwarz, David A Schwartz
Journal: Nature Genetics (2013)
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors
Authors: Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmaña, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Montes, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, Ronnie Shapira-Frommer
Journal: Clinical Cancer Research (2017)

Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor. This phase I-II study was the first to evaluate single-agent oral rucaparib at multiple doses.Experimental Design: Part 1 (phase I) sought to determine the MTD, recommended phase II dose (RP2D), and pharmacokinetics of oral rucaparib administered in 21-day continuous cycles in patients with advanced solid tumors. Part 2A (phase II) enrolled patients with platinum-sensitive, high-grade ovarian carcinoma (HGOC) associated with a germline BRCA1/2 mutation who received two to four prior regimens and had a progression-free interval of 6 months or more following their most recent platinum therapy. The primary endpoint was investigator-assessed objective response rate (ORR) by RECIST version 1.1.Results: In part 1, 56 patients received oral rucaparib (40 to 500 mg once daily and 240 to 840 mg twice daily). No MTD was identified per protocol-defined criteria; 600 mg twice daily was selected as the RP2D based on manageable toxicity and clinical activity. Pharmacokinetics were approximately dose-proportional across all dose levels. In part 2A, 42 patients with germline BRCA1/2-mutated HGOC received rucaparib 600 mg twice daily. Investigator-assessed ORR was 59.5%. The most common treatment-emergent adverse events (all grades) were asthenia/fatigue (85.7%; 36/42), nausea (83.3%; 35/42), anemia (71.4%; 30/42), alanine transaminase and/or aspartate transaminase elevations (57.1%; 24/42), and vomiting (54.8%; 23/42). Among 98 patients, 5 (5.1%) discontinued because of an adverse event (excluding disease progression).Conclusions: Rucaparib was tolerable and had activity in patients with platinum-sensitive germline BRCA1/2-mutated HGOC. Clin Cancer Res; 23(15); 4095-106. ©2017 AACR.
Granulocyte-Colony Stimulating Factor Decreases Angina and Improves Exercise Capacity in Patients with Chronic Refractory ‘No Option’ Ischemic Heart Disease.
Authors: David D.F. Ma, Jason C. Kovacic, Anthony Dodds, Helen Tao, Peter McDonald, Michael P. Feneley, David W. Muller, Judith Fruend, Sam Milliken, John Moore, Silviu Itescu, Robert M. Graham
Journal: Blood (2005)
Very Rapid Clearance after a Joint Bleed Knee Can Not Prevent Adverse Effects on Cartilage and Synovial Tissue: A Canine in Vivo Study.
Authors: Nathalie W.D. Jansen, Goris Roosendaal, Marion Wenting, Herman A.W. Hazewinkel, Johannes W.J. Bijlsma, Matthias Theobald, Floris P.J.G. Lafeber
Journal: Blood (2008)
Abstract P5-08-17: Breast cancer in octagenerians: A community hospital experience
Authors: V Gadiyaram, D Caldwell
Journal: Cancer Research (2017)

Abstract Background : Breast cancer incidence increases with age. However Elderly patients are undertreated and underdiagnosed affecting their overall survival with limited availabilty of clinical trial data Patients and Methods : We used the data from our cancer registry to evaluate the cases of breast cancer diagnosed between the years 2005-2010 with follow up data available to date to examine the method of diagnosis(mammogram vs palpable abnormality ), Age at diagnosis, Stage at diagnosis, Type of surgery (BCT Vs Mastectomy ), Receptor status(ER/PR/Her 2 neu) and treatment's received ( Hormonal therapy , Radiation therapy and chemotherapy) and average survival after the diagnosis of breast cancer. Data regarding the causality of death was not readily available as part of the registry data. Results : A total of 495 breast cancer cases diagnosed in the years between 2005-2010 wee identified ., Median age at diagnosis was 85 with ages ranging from 81-102 .Out of the 495 patients 55 % were diagnosed with a mammogramand 41 % by palpable abnormality. Patients were diagnosed at Stage 0,1,2,3,4 (12%,45 %,7% ,3 %. 55% underwent Lumpectomy and 31 % underwent Mastectomy .82 % and 18 % ER negative. Her 2 data was only available in 59 patients, out of those tested only 4 Her 2 positive. , Radiation(34 %) /Chemo(6 %)/ Hormone(34%) ,Radiation/Chemo 2 % ,Radiation/Hormone 18%, Chemo/Hormon 2% , 41 % didn't proceed with any treatments.Median survival was 54 months and Average survival was 56 months. Median survival 54 months and average survival was 56 months, With 203 patients alive at the end of 5 years with mortality of about 62 %. However we do not have the data of causality of death in these patient . Comparison between Age Groups : See table below Comparision of data b/n Age groupsAge at Diagnosis80-8485-8990 +No of patients24419256Mammogram13810532Palpable Lump947924Lumpectomy1576724Mastectomy803026Average Survival in months84.54848.5 Conclusion: Even though Surgery was performed in most the patients , Only 50 % or lesser number of patients had Adjuvant treatment with Endocrine , Radiation and chemotherapy. Based on the data even though most patient were diagnosed with early stage breast cancer , had significantly poor survival with median survival of about 54 months . With Survival dramatically dropped from 84 months to 48 months in patient 85 + years of age. Citation Format: Gadiyaram V, Caldwell D. Breast cancer in octagenerians: A community hospital experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-17.
ISIS-FXIRx, a Potent Antisense Inhibitor of Factor XI, Suppresses FXI Activity and Elevates Aptt without Increased Risk of Bleeding in Cynomolgus Monkeys Following 13 Weeks of Treatment
Authors: Husam Younis, Jeff R. Crosby, Chenguang Zhao, Robert MacLeod, Brett P. Monia, Scott Henry
Journal: Blood (2011)
An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors
Authors: Eduardo Olavarria, Michael Schleuning, Simona Iacobelli, Jennifer Hoek, Henric-Jan Blok, Mahmoud Aljurf, Boris V Afanasyev, Liisa Volin, Henrik Sengeloev, Tamás Masszi, Jakob Passweg, Gérard Socié, Paul Browne, Arnold Ganser, Slawomira Kyrcz-Krzemien, Arnon Nagler, John A Snowden, Harry C. Schouten, Mauricette Michallet, Carmino de Sousa, Theo de Witte, Yves Chalandon, Nicolaus Kröger
Journal: Blood (2016)
Significant Decrement of Serum Ferritin By Pretransplant Iron Chelating Therapy with Deferasirox Is a Favorable Prognostic Factor in Iron-Overloaded Patients with Severe Apastic Anemia Undergoing Allogeneic Stem Cell Transplantation
Authors: Sung-Eun Lee, Young-Woo Jeon, Jae-Ho Yoon, Seung-Hwan Shin, Seung-Ah Yahng, Byung-Sik Cho, Ki-Sung Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Hee-Je Kim, Seok-Goo Cho, Dong-Wook Kim, Woo-Sung Min, Jong Wook Lee
Journal: Blood (2014)
Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.
Authors: Ajoy K. Samanta, Sandip Chakravorty, Yan Wang, Jorge Cortes, Hagop Kantarjian, Richard E. Champlin, Danilo Perrotti, Ralph B. Arlinghaus
Journal: Blood (2007)
The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML Cells Both In Vitro and In Vivo.
Authors: Deepa B. Shankar, Jenny C. Chang, Bertrand Parcells, Salemiz Sandoval, Junling Li, Ru-Qi Wei, Paul Tapang, Steven K. Davidsen, Dan H. Albert, Keith B. Glaser, Theodore B. Moore, Kathleen M. Sakamoto
Journal: Blood (2005)
Steroid modified tinea
Authors: Shyam Verma
Journal: BMJ (2017)

#### What you need to know

A 24 year old man complains of a severely itchy rash in the groin which had spread to his thighs and penis over two months (fig 1⇓). He had bought and applied a cream from a pharmacy which had helped a bit at first; it contained clobetasol, ofloxacin, terbinafine, and ornidazole.



Fig 1  Extensive tinea cruris and tinea corporis with erythematous, eczematous, and scaly lesions in groin, both thighs, and penis



Tinea is a superficial fungal infection caused by dermatophytes. The lesions are typically annular with an erythematous scaly advancing edge with or without central clearing. Itching is common. Tinea is simple to diagnose and treat with oral and topical antifungal agents.1

However, topical corticosteroids or steroid-containing antifungal creams are commonly used, particularly in …
Abstract P2-03-11: Genomic pattern of breast carcinomas carrying mutations of non-<i>BRCA</i> homologous recombination genes
Authors: P-H Lin, W-H Kuo, M-Y Wang, C Lo, C-H Lin, Y-S Lu, C-F Chiu, C-S Huang
Journal: Cancer Research (2017)

Abstract Background BRCA1 and BRCA2 are involved in the homologous recombination (HR) double-strand DNA break repair and genomic patterns of breast tumors with defective BRCA are characterized by increased genomic instability. The pre-clinical and clinical studies show that tumors with defective BRCA or other HR genes can response to platinum and PARP inhibitors. However, the genomic pattern of tumors carrying mutations of non-BRCA HR genes are not investigated. Methods Genomic patterns of breast carcinomas were performed by comparative genomic hybridization (CGH) array containing 60000 probes covering the whole genome with an average spacing of 40kb. The frequency of gains and losses for each regions detected by probes was calculated by ratio thresholds of 0.25 and -0.25, respectively. Large-scale genomic structural aberration was defined as the region of gains and losses of at least 10Mb. We analyzed the difference of large-scale aberration, including numbers, length and specific regions, between tumors with BRCA mutation (mtBRCA), non-BRCA HR mutation (mtHR) and wild type. Results We examined 41 breast carcinomas, including 15 cases with BRCA mutations, 14 with non-BRCA HR gene mutations and 12 without mutations (control). The 14 non-BRCA HR gene were 1 ATM, 1 BRIP1, 1 BARD1, 1 FANCA, 2 FANCB, 1 FANCI, 1 PALB2, 2 RAD50, 2 RAD51C and 2 RAD51D. The number and length of large-scale genomic structural aberration of mtBRCA tumors were significantly higher than wild type tumors (number p=0.005; length p=0.005), indicating CGH can distinguish the mtBRCA from control tumors. We then checked the mtHR tumors, which also revealed significantly increased number and longer length of structural aberrations compared to wild type tumors (number p=0.035; length p=0.022), but were not different from mtBRCA tumors (number p=0.204; length p=0.425). Among the specific regions on chromosomes, mtBRCA and mtHR tumors contained similar genomic aberration regions but different from wild type tumors. The most frequent aberration regions of mtBRCA and mtHR tumors are chromosome 6p22.1-p25, 6q21-q27, 8q11.1-q24, 11p11.2-p14.1, 11q, 12p and 19p, which are less revealed in the wild type (all p value &amp;lt;0.05). Conclusions Our study demonstrated a direct evidence that increased genomic instability were the common characteristics of mtBRCA and non-BRCA mtHR tumors. In addition, we identify the specific genomic patterns of mtBRCA and mtHR tumors, which can be a biomarker indicating HR deficiency and response to platinum and PARP inhibitors. Citation Format: Lin P-H, Kuo W-H, Wang M-Y, Lo C, Lin C-H, Lu Y-S, Chiu C-F, Huang C-S. Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-11.
MGMT expression in low-grade gliomas
Authors: Y. Lin, T. Jiang, G. Li
Journal: Journal of Clinical Oncology (2009)

e13001 Background: To evaluate the expression of MGMT in low-grade gliomas, and explore the relationship between its expression and the histological type of the tumour and the corresponding MRI characteristics. Methods: We assessed 389 low-grade gliomas (182 astrocytomas, 145 oligoastrocytomas, 61 oligodendrocytomas) with immunohistochemistry staining. We also recorded the preoperational MRI criteria such as tumor volume on T2 image, enhancing volume, tumor location, and relationship with ventricles. Results: The expression of MGMT in astrocytomas, oligoastrocytomas, and oligocytomas were 1.67 ± 0.78, 1.41 ± 0.86,1.44 ± 0.78, respectively. Significant stronger expression of MGMT was observed in astrocytomas than oligoastrocytomas and oligodendrocytomas (t = 3.00, p = 0.03), but no significant difference was observed between the latter two (t = 0.28, p = 0.78). MGMT expression level was significantly correlated with the enhancing volume of the tumor (r = -0.605, p = 0.002), but did not correlate with the total tumor volume (p = 0.504). Conclusions: MGMT is more strongly expressed in tumors of solely astrocyte component, and its expression level is negatively correlated with the extent of blood-brain barrier disruption. This suggest that MGMT may contribute to the tumor resistance to radiotherapy and chemotherapy in low-grade gliomas. No significant financial relationships to disclose.
Fresh evidence links adiposity with multiple cancers
Authors: Yikyung Park, Graham A Colditz
Journal: BMJ (2017)

The association is now clear; it’s time to get serious about prevention

The International Agency for Research on Cancer (IARC) working group recently reviewed epidemiological data, studies in experimental animals, and mechanistic data and concluded that excess body fatness causes cancer of the colon and rectum, liver, gallbladder, pancreas, kidney, thyroid, breast (postmenopausal), endometrium, ovary, oesophagus (adenocarcinoma), and gastric cardia, as well as meningioma and multiple myeloma.1 This potentially makes excess body fat the second most important modifiable cancer risk factor after tobacco use.

The study by Kyrgiou and colleagues2 took up the challenge of evaluating the robustness of multiple, sometimes overlapping, meta-analyses that reported an association between body adiposity measures (such as body mass index, weight gain, and waist circumference) and cancer. The authors conducted an umbrella review, also known as a “review of reviews” or “meta-review,”34 and initially identified a total of 204 individual meta-analyses from 49 papers. They further examined the 95 meta-analyses that reported the association between body fatness measured on a continuous scale (mostly body …